24,998 Shares in CareDx, Inc (NASDAQ:CDNA) Purchased by Hanseatic Management Services Inc.

Hanseatic Management Services Inc. bought a new position in CareDx, Inc (NASDAQ:CDNA) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 24,998 shares of the company’s stock, valued at approximately $781,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in CDNA. Millennium Management LLC raised its holdings in shares of CareDx by 1,085.4% in the 2nd quarter. Millennium Management LLC now owns 2,140,909 shares of the company’s stock worth $33,248,000 after acquiring an additional 1,960,308 shares during the last quarter. Bamco Inc. NY purchased a new stake in CareDx in the 1st quarter valued at about $13,025,000. Fred Alger Management LLC increased its stake in CareDx by 517.9% in the 2nd quarter. Fred Alger Management LLC now owns 1,149,602 shares of the company’s stock valued at $17,853,000 after buying an additional 963,554 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of CareDx by 868.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 204,987 shares of the company’s stock valued at $6,401,000 after acquiring an additional 183,823 shares during the period. Finally, Driehaus Capital Management LLC bought a new position in shares of CareDx during the 2nd quarter valued at approximately $2,852,000.

Insiders Place Their Bets

In other CareDx news, Director Peter Maag sold 35,552 shares of CareDx stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $33.04, for a total value of $1,174,638.08. Following the completion of the sale, the director now owns 330,024 shares of the company’s stock, valued at approximately $10,903,992.96. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Peter Maag sold 35,552 shares of CareDx stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $33.04, for a total value of $1,174,638.08. Following the completion of the sale, the director now owns 330,024 shares of the company’s stock, valued at $10,903,992.96. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Alexander L. Johnson sold 21,557 shares of CareDx stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $32.58, for a total value of $702,327.06. Following the transaction, the insider now owns 284,983 shares in the company, valued at $9,284,746.14. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 91,340 shares of company stock valued at $3,025,415. Corporate insiders own 4.90% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on CDNA shares. Craig Hallum increased their target price on shares of CareDx from $22.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. The Goldman Sachs Group increased their target price on shares of CareDx from $26.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Wells Fargo & Company started coverage on shares of CareDx in a research report on Tuesday, August 27th. They set an “underweight” rating and a $28.00 target price for the company. HC Wainwright reaffirmed a “neutral” rating on shares of CareDx in a report on Tuesday, October 22nd. Finally, StockNews.com raised shares of CareDx from a “hold” rating to a “buy” rating in a report on Thursday, October 17th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, CareDx currently has an average rating of “Moderate Buy” and a consensus target price of $29.60.

CareDx Stock Up 1.4 %

CDNA opened at $23.21 on Thursday. The stock has a market cap of $1.22 billion, a PE ratio of -8.60 and a beta of 1.80. The business has a 50 day moving average of $27.56 and a 200-day moving average of $20.97. CareDx, Inc has a 52 week low of $6.11 and a 52 week high of $34.84.

CareDx (NASDAQ:CDNA) last released its earnings results on Monday, November 4th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.11. The company had revenue of $82.88 million during the quarter, compared to analysts’ expectations of $80.04 million. CareDx had a negative return on equity of 53.65% and a negative net margin of 53.73%. The firm’s revenue for the quarter was up 23.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.43) EPS. Equities analysts anticipate that CareDx, Inc will post -0.83 EPS for the current year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.